Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis | Zendy

Sheryl Zelenitsky | Zendy; Nathan P. Beahm | Zendy; Harris Iacovides | Zendy; Robert E. Ariano | Zendy; George G. Zhanel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis

Author(s) -

Sheryl Zelenitsky,

Nathan P. Beahm,

Harris Iacovides,

Robert E. Ariano,

George G. Zhanel

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky120

Subject(s) - cefazolin , ceftriaxone , pharmacodynamics , dosing , medicine , pharmacology , pharmacokinetics , antibiotics , microbiology and biotechnology , biology

Despite the convenience of once-daily dosing, the use of ceftriaxone for Staphylococcus aureus infections has significant limitations, including scarce clinical evidence and increasingly questionable pharmacodynamic activity. Our goal was to conduct an integrated pharmacokinetic-pharmacodynamic analysis of the appropriateness of ceftriaxone compared with cefazolin for treating serious MSSA infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research